Drug intelligence / Profile preview

Ziyin Yangshen decoction granules

Development stage: Unknown
Lead developer: Shuguang Hospital
Administration: Oral

Overview

Ziyin Yangshen decoction granules is a Traditional Chinese Medicine (TCM) formulation developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is designed to treat heart failure with preserved ejection fraction (HFpEF) by applying the TCM principles of nourishing Yin and tonifying the kidney (or tranquilizing the spirit). The drug is currently being evaluated in a randomized, double-blind, placebo-controlled multicenter Phase 1 clinical trial in China. In this study, it is administered alongside standard therapy to assess its efficacy in improving 180-day cardiovascular outcomes and symptoms, as well as its impact on multi-omics biomarkers in patients with HFpEF.

Other names: Ziyin Yangshen decoction granules

Beyond the preview

Go deeper on Ziyin Yangshen decoction granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ziyin Yangshen decoction granules.

Explore the full profile